Apothecary Pharma Recalls Compounded Tirzepatide and NAD+ Injections Due to Sterility Concerns

Apothecary Pharma LLC is voluntarily recalling compounded tirzepatide and NAD+ injectables nationwide because the company cannot assure the products are sterile. The U.S. Food and Drug Administration (FDA) classified this as a Class II recall, indicating that exposure may cause temporary or medically reversible health problems. The recall, initiated on September 24, covers 22 vials of Tirzepatide Injection and one vial of Apothecary NAD+ Injection.